Carregant...
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain
Synthesis inhibition is the basis for the treatment of type 1 Gaucher disease by the glucosylceramide synthase (GCS) inhibitor eliglustat tartrate. However, the extended use of eliglustat and related compounds for the treatment of glycosphingolipid storage diseases with CNS manifestations is limited...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The American Society for Biochemistry and Molecular Biology
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3269155/ https://ncbi.nlm.nih.gov/pubmed/22058426 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M021261 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|